


Iron Halide-Mediated Regio- and Stereoselective Halosulfonylation of Terminal Alkynes with Sulfonylhydrazides: Synthesis of (*E*)- β -Chloro and Bromo Vinylsulfones

Xiaoqing Li,* Xinhua Shi, Mingwu Fang, and Xiangsheng Xu*

College of Chemical Engineering and Materials Science, Zhejiang University of Technology, Hangzhou 310014, People's Republic of China

S Supporting Information

ABSTRACT: Halosulfonylation of terminal alkynes was achieved with sulfonylhydrazides as the sulfonyl precursor and inexpensive iron halide as halide source in the presence of TBHP, allowing the regio- and stereoselective generation of (*E*)- β -chloro and bromo vinylsulfones.



Functionalized alkenes are one of the most broadly existing structural motifs present in organic molecules. The difunctionalization of alkynes represents a particularly useful contribution to their synthesis.¹ In this context, halosulfonylation of terminal alkynes has attracted considerable attention^{2,3} because both the vinyl halide⁴ and vinyl sulfone moiety⁵ in the resulting β -halide vinylsulfones are important intermediates in organic synthesis. Generally, sulfonyl bromides and iodides were applied as halosulfonylation reagents under thermal or photochemical conditions.² Alternative copper-catalyzed methods using more practical sulfonyl chlorides are also investigated.³ Recently, Nakamura and co-workers demonstrated a highly regio- and stereoselective Fe(acac)₃-catalyzed chlorosulfonylation with aromatic sulfonyl chlorides.⁶ However, the usage of a phosphine ligand and harsh reaction conditions restricted their practical utility on a larger scale process. In recent years, we have focused our efforts on the construction of sulfone-containing molecules based on sulfonyl radical addition using sulfonylhydrazides as the sulfonyl precursor.⁷ It has been found that FeCl₃ could act as Cl source in some radical reactions.⁸ In light of these factors, we hypothesized that the combination of sulfonylhydrazides with FeCl₃ might be utilized to allow chlorosulfonylation of alkynes. Herein, we present a full account of this work including extension to bromo-sulfonylation by using FeBr₃ as the Br source.

We initially examined the chlorosulfonylation of phenylacetylene **1a** with *p*-toluenesulfonylhydrazide (TsNHNH₂) **2a** and FeCl₃·6H₂O in the presence of 2 equiv of TBHP as the oxidant (Table 1). After screening the loading of FeCl₃·6H₂O (entries 1–3), 2.0 equiv afforded the best result, providing (*E*)- β -chloro vinylsulfone **3aa** in 95% yield (entry 2). Notably, this reaction exhibited high selectivity, and no other isomers were observed. The reaction worked equally well with anhydrous FeCl₃ (entry 4), whereas no desired product was isolated by using LiCl as the chloride source (entry 5). Reducing the amount of TsNHNH₂ led to a lower yield (entry 6). The reaction in water did not work (entry 7), while other solvents,

Table 1. Optimized Reaction Conditions^a

entry	Cl source (equiv)	solvent	yield (%)
1	FeCl ₃ ·6H ₂ O (1.5)	MeCN	74
2	FeCl ₃ ·6H ₂ O (2.0)	MeCN	95
3	FeCl ₃ ·6H ₂ O (2.5)	MeCN	87
4	FeCl ₃ (2.0)	MeCN	94
5	LiCl (2.0)	MeCN	trace
6 ^b	FeCl ₃ ·6H ₂ O (2.0)	MeCN	88
7	FeCl ₃ ·6H ₂ O (2.0)	H ₂ O	trace
8	FeCl ₃ ·6H ₂ O (2.0)	EtOAc	83
9	FeCl ₃ ·6H ₂ O (2.0)	DCE	64
10	FeCl ₃ ·6H ₂ O (2.0)	toluene	67
11	FeCl ₃ ·6H ₂ O (2.0)	dioxane	68


^aReaction conditions: alkynes (0.5 mmol), sulfonylhydrazides (1.4 equiv), Cl source, and TBHP (2 equiv, 70% water solution) in CH₃CN (2 mL) at 80 °C for 3 h. ^b1.2 equiv of TsNHNH₂ was used.

such as EtOAc, DCE, toluene, and dioxane, were less effective (entries 8–11).

Encouraged by these results, we applied the above chlorosulfonylation protocol to a range of alkynes **1** and arylsulfonylhydrazides **2** (Table 2). The scope of arylsulfonylhydrazides **2** was initially explored in the presence of phenylacetylene **1a**. Gratifyingly, introduction of Me, MeO, and halogen groups into the phenyl ring of sulfonylhydrazides was well-tolerated, and the chlorosulfonylation products were isolated in good to excellent yield. Then, the scope of alkynes **1** was explored in the reaction with TsNHNH₂ (**2a**). Aromatic alkynes with a wide range of functional groups, such as Me, (CH₂)₄CH₃, MeO, CH₃(CH₂)₄O, F, Cl, Br, and CF₃, were well-tolerated (products

Received: July 21, 2013

Published: August 27, 2013

Table 2. FeCl₃·6H₂O-Mediated Chlorosulfonylation of Alkynes with Sulfonylhydrazides^a

^aReaction conditions: alkynes (0.5 mmol), sulfonylhydrazides (1.4 equiv), FeCl₃·6H₂O (2 equiv), and TBHP (2 equiv, 70% water solution) in CH₃CN (2 mL) at 80 °C for 3 h.

3ba–3ma). The majority of the alkynes with *para*-substitutions gave good yields, while the *ortho*- and *meta*-substituted alkynes afforded a slightly lower yield. Thiophenyl-substituted alkyne could also be employed in this reaction to afford the product 3na in moderate yields. Notably, aliphatic alkyne successfully underwent halosulfonylation give 3oa, albeit in a low yield. However, the internal alkyne failed in the reaction to give the desired product 3pa due to the steric effect. To our delight, the known compounds are formed in higher yields under milder reaction conditions compared with the reported method.⁹

Inspired by the excellent results above, we initiated further studies of bromosulfonylation by replacing FeCl₃·6H₂O with FeBr₃. As described in Table 3, with various alkynes and sulfonylhydrazides examined in the chlorosulfonylation reaction (Table 2), the desired (*E*)- β -bromo vinylsulfones were successfully achieved in the presence of FeBr₃ under the optimal reaction conditions. Generally, bromosulfonylation exhibited slightly lower reactivity than chlorosulfonylation, giving moderate yields.


On the basis of the above results and literature reports,^{4,6,10} the proposed mechanism is illustrated in Scheme 1. Initially, the *tert*-butoxyl and *tert*-butylperoxy radicals were generated in an iron catalyst–TBHP catalytic system.¹⁰ Then, hydrogen abstraction of sulfonylhydrazides by the resultant radicals generated sulfonyl radicals from a series of steps with the

release of molecular nitrogen.⁴ The iron halide also acted as a Lewis acid to activate the alkynes. Subsequently, the radical addition of sulfonyl radicals to the Fe-coordinated alkynes (A) from the opposite side of the Fe moiety at the terminal position would lead to regio- and stereoselective formation of the Fe(IV) intermediate (B). Finally, reductive elimination of Fe(IV) intermediate B occurred to afford the (*E*)- β -halo-vinylsulfones with the generation of the Fe(II) catalyst. Notably, the formation of sulfonyl halide (C) was detected in the halosulfonylation, which probably was due to the direct trapping of the sulfonyl radicals with a halide atom of the iron halide.⁸ Thus we speculated that the difference in the reactivity between chlorosulfonylation and bromosulfonylation might result from the easier abstraction of Br than Cl by sulfonyl radicals.

In summary, we have developed a highly regio- and stereoselective oxidative halosulfonylation of alkynes using sulfonylhydrazides as the sulfonyl precursor and inexpensive iron halide as the halide source. It provides efficient and general access to both (*E*)- β -chloro and bromo vinylsulfones.


EXPERIMENTAL SECTION

General Procedures. All reagents and solvents were used without purification. FeCl₃·6H₂O and FeCl₃ was purchased from Sinopharm Chemical (≥ 99 and $\geq 97\%$, respectively). FeBr₃ was purchased from J&K Chemical (97%). Melting points are uncorrected. The ¹H NMR

Table 3. FeBr₃-Mediated Bromosulfonylation of Alkynes with Sulfonylhydrazides^a

^aReaction conditions: alkynes (0.5 mmol), sulfonylhydrazides (1.4 equiv), FeBr₃ (2 equiv), and TBHP (2 equiv, 70% water solution) in CH₃CN (2 mL) at 80 °C for 3 h.

Scheme 1. Proposed Mechanism



and ¹³C NMR spectra were recorded at 25 °C in CDCl₃ at 500 and 125 MHz, respectively, with TMS as the internal standard. Chemical shifts (δ) are expressed in parts per million, and coupling constants J

are given in hertz. High-resolution mass spectra (HRMS) were obtained on a TOF MS instrument with APCI source.

Typical Procedure for the Synthesis of (E)-β-Haloalkenylsulfones. To a solution of sulfonylhydrazides (0.7 mmol), FeCl₃·6H₂O, or FeBr₃ (1.0 mmol) in CH₃CN (2 mL) were added alkynes (0.5 mmol) and TBHP (1.0 mmol, 70% water solution), and the mixture was stirred at 80 °C for 3 h. After removal of solvent under reduced pressure, the residue was purified by chromatography (petroleum/ethyl acetate = 20:1) to give the desired products.

(E)-1-((2-Chloro-2-phenylvinyl)sulfonyl)-4-methylbenzene (**3aa**):⁶ white solid (138.8 mg, 95%); mp 97–98 °C; ¹H NMR (500 MHz, CDCl₃) δ 7.50 (d, J = 8.3 Hz, 2H), 7.42 (m, 1H), 7.39–7.33 (m, 4H), 7.20 (d, J = 8.2 Hz, 2H), 6.92 (s, 1H), 2.39 (s, 3H); ¹³C NMR (125 MHz, CDCl₃) δ 147.9, 144.6, 137.6, 134.4, 131.0, 130.6, 129.6, 128.8, 128.0, 127.8, 21.6.

(E)-1-((2-Chloro-2-(phenylsulfonyl)vinyl)benzene (**3ab**): white solid (108.5 mg, 78%); mp 73–74 °C; ¹H NMR (500 MHz, CDCl₃) δ 7.61 (dd, J = 8.5, 1.2 Hz, 2H), 7.56–7.52 (m, 1H), 7.44–7.40 (m, 2H), 7.40–7.32 (m, 5H), 6.95 (s, 1H); ¹³C NMR (125 MHz, CDCl₃) δ 148.5, 140.5, 134.3, 133.5, 130.9, 130.7, 129.0, 128.8, 128.1, 127.7; HRMS (APCI) calcd for C₁₄H₁₂ClO₂S (M + H)⁺ 279.0247, found 279.0244.

(E)-1-((2-Chloro-2-(phenylsulfonyl)vinyl)sulfonyl)-4-methoxybenzene (**3ac**):⁶ white solid (126.4 mg, 82%); mp 104–106 °C; ¹H NMR (500 MHz, CDCl₃) δ 7.53 (d, J = 8.9 Hz, 2H), 7.42 (m, 1H), 7.39–7.34 (m, 4H), 6.93 (s, 1H), 6.85 (d, J = 8.9 Hz, 2H), 3.84 (s, 3H); ¹³C NMR (125 MHz, CDCl₃) δ 163.7, 147.5, 134.4, 132.0, 131.4, 130.6, 130.0, 128.9, 128.0, 114.2, 55.7.

(E)-1-Chloro-4-((2-chloro-2-phenylvinyl)sulfonyl)benzene (**3ad**):⁶ white solid (125.0 mg, 80%); mp 107–108 °C; ¹H NMR (500 MHz, CDCl₃) δ 7.50 (d, J = 8.7 Hz, 2H), 7.45–7.41 (m, 1H), 7.36–7.33 (m, 6H), 6.94 (s, 1H); ¹³C NMR (125 MHz, CDCl₃) δ 149.0, 140.3, 138.9, 134.1, 130.9, 130.7, 129.2, 129.2, 128.8, 128.1.

(*E*)-1-Bromo-4-((2-chloro-2-phenylvinyl)sulfonyl)benzene (**3ae**): white solid (161.3 mg, 90%); mp 103–104 °C; ¹H NMR (500 MHz, CDCl₃) δ 7.50 (d, *J* = 8.7 Hz, 2H), 7.43 (t, *J* = 2.1 Hz, 2H), 7.41 (d, *J* = 1.8 Hz, 1H), 7.34 (d, *J* = 1.6 Hz, 2H), 7.34 (s, 2H), 6.94 (s, 1H); ¹³C NMR (125 MHz, CDCl₃) δ 149.0, 139.4, 134.1, 132.2, 130.8, 130.6, 129.2, 128.8, 128.7, 128.0; HRMS (APCI) calcd for C₁₄H₁₁BrClO₂S (M + H)⁺ 356.9352, found 356.9348.

(*E*)-1-((2-Chloro-2-(*p*-tolyl)vinyl)sulfonyl)-4-methylbenzene (**3ba**): white solid (125.5 mg, 82%); mp 135–137 °C; ¹H NMR (500 MHz, CDCl₃) δ 7.54 (d, *J* = 8.3 Hz, 2H), 7.31 (d, *J* = 8.2 Hz, 2H), 7.22 (d, *J* = 8.0 Hz, 2H), 7.17 (d, *J* = 7.9 Hz, 2H), 6.86 (s, 1H), 2.40 (s, 3H), 2.39 (s, 3H); ¹³C NMR (125 MHz, CDCl₃) δ 148.2, 144.6, 141.2, 137.8, 131.5, 130.3, 129.6, 128.9, 128.7, 127.8, 21.6, 21.5; HRMS (APCI) calcd for C₁₆H₁₆ClO₂S (M + H)⁺ 307.0560, found 307.0557.

(*E*)-1-((2-Chloro-2-(4-pentylphenyl)vinyl)sulfonyl)-4-methylbenzene (**3ca**): pale oil (154.7 mg, 85%); ¹H NMR (500 MHz, CDCl₃) δ 7.50 (d, *J* = 8.3 Hz, 2H), 7.31 (d, *J* = 8.2 Hz, 2H), 7.18 (d, *J* = 8.0 Hz, 2H), 7.15 (d, *J* = 8.3 Hz, 2H), 6.89 (s, 1H), 2.64–2.61 (m, 2H), 2.38 (s, 3H), 1.65–1.61 (m, 2H), 1.37–1.33 (m, 4H), 0.92 (t, *J* = 7.0 Hz, 3H); ¹³C NMR (125 MHz, CDCl₃) δ 148.3, 146.2, 144.4, 137.8, 131.6, 130.5, 129.5, 129.0, 128.0, 127.8, 35.8, 31.5, 30.9, 22.5, 21.6, 14.0; HRMS (APCI) calcd for C₂₀H₂₄ClO₂S (M + H)⁺ 363.1186, found 363.1182.

(*E*)-1-((2-Chloro-2-(4-methoxyphenyl)vinyl)sulfonyl)-4-methylbenzene (**3da**):⁶ white solid (118.7 mg, 74%); mp 85–86 °C; ¹H NMR (500 MHz, CDCl₃) δ 7.55 (d, *J* = 8.3 Hz, 2H), 7.41 (d, *J* = 8.9 Hz, 2H), 7.22 (d, *J* = 8.0 Hz, 2H), 6.87 (d, *J* = 8.9 Hz, 2H), 6.83 (s, 1H), 3.85 (s, 3H), 2.40 (s, 3H); ¹³C NMR (125 MHz, CDCl₃) δ 161.7, 148.0, 144.5, 137.9, 131.0, 129.7, 129.6, 127.7, 126.5, 113.4, 55.4, 21.6.

(*E*)-1-((2-Chloro-2-(4-(pentyl)oxy)phenyl)vinyl)sulfonyl)-4-methylbenzene (**3ea**): pale oil (110.3 mg, 52%); ¹H NMR (500 MHz, CDCl₃) δ 7.56 (d, *J* = 8.3 Hz, 2H), 7.41 (d, *J* = 8.8 Hz, 2H), 7.22 (d, *J* = 8.1 Hz, 2H), 6.86 (d, *J* = 8.8 Hz, 2H), 6.84 (s, 1H), 3.99 (t, *J* = 6.5 Hz, 2H), 2.40 (s, 3H), 1.83–1.79 (m, 2H), 1.48–1.40 (m, 4H), 0.96 (t, *J* = 7.1 Hz, 3H); ¹³C NMR (125 MHz, CDCl₃) δ 161.2, 148.0, 144.4, 137.8, 130.9, 129.6, 129.4, 127.6, 126.1, 113.7, 68.1, 28.7, 28.1, 22.3, 21.5, 13.9; HRMS (APCI) calcd for C₂₀H₂₄ClO₃S (M + H)⁺ 379.1135, found 379.1132.

(*E*)-1-((2-Chloro-2-(4-fluorophenyl)vinyl)sulfonyl)-4-methylbenzene (**3fa**):⁶ white solid (128.3 mg, 83%); mp 98–99 °C; ¹H NMR (500 MHz, CDCl₃) δ 7.53 (d, *J* = 8.3 Hz, 2H), 7.41 (dd, *J* = 8.9, 5.2 Hz, 2H), 7.24 (dd, *J* = 8.4, 0.5 Hz, 2H), 7.05 (t, *J* = 8.7 Hz, 2H), 6.91 (s, 1H), 2.41 (s, 3H); ¹³C NMR (125 MHz, CDCl₃) δ 164.0 (d, *J* = 250.6 Hz), 146.7, 144.9, 137.6, 131.3, 131.2, 130.4 (d, *J* = 3.4 Hz), 129.8, 127.7, 115.3 (d, *J* = 22.0 Hz), 21.6.

(*E*)-1-Chloro-4-(1-chloro-2-tosylvinyl)benzene (**3ga**): white solid (128.9 mg, 79%); mp 96–98 °C; ¹H NMR (500 MHz, CDCl₃) δ 7.54 (d, *J* = 8.3 Hz, 2H), 7.34 (s, 4H), 7.25 (d, *J* = 8.0 Hz, 2H), 6.91 (s, 1H), 2.41 (s, 3H); ¹³C NMR (125 MHz, CDCl₃) δ 146.3, 144.9, 137.5, 137.0, 132.7, 131.4, 130.3, 129.8, 128.3, 127.8, 21.6; HRMS (APCI) calcd for C₁₅H₁₃Cl₂O₂S (M + H)⁺ 327.0013, found 327.0015.

(*E*)-1-Bromo-4-(1-chloro-2-tosylvinyl)benzene (**3ha**): white solid (139.6 mg, 75%); mp 101–103 °C; ¹H NMR (500 MHz, CDCl₃) δ 7.54 (d, *J* = 8.3 Hz, 2H), 7.49 (d, *J* = 8.5 Hz, 2H), 7.27 (d, *J* = 8.5 Hz, 2H), 7.24 (d, *J* = 8.0 Hz, 2H), 6.91 (s, 1H), 2.40 (s, 3H); ¹³C NMR (125 MHz, CDCl₃) δ 146.3, 145.0, 137.4, 133.2, 131.5, 131.3, 130.5, 129.8, 127.8, 125.3, 21.6; HRMS (APCI) calcd for C₁₅H₁₃BrClO₂S (M + H)⁺ 370.9508, found 370.9506.

(*E*)-1-Chloro-3-(1-chloro-2-tosylvinyl)benzene (**3ia**): white solid (109.9 mg, 67%); mp 87–89 °C; ¹H NMR (500 MHz, CDCl₃) δ 7.51 (d, *J* = 8.3 Hz, 2H), 7.340–7.37 (m, 1H), 7.31 (d, *J* = 5.0 Hz, 2H), 7.23 (dd, *J* = 14.5, 6.4 Hz, 3H), 6.96 (s, 1H), 2.41 (s, 3H); ¹³C NMR (125 MHz, CDCl₃) δ 145.8, 145.0, 137.3, 135.9, 134.1, 132.2, 130.6, 129.8, 129.39, 128.5, 127.8, 127.2, 21.6; HRMS (APCI) calcd for C₁₅H₁₃Cl₂O₂S (M + H)⁺ 327.0013, found 327.0011.

(*E*)-1-Bromo-3-(1-chloro-2-tosylvinyl)benzene (**3ja**): white solid (128.4 mg, 69%); mp 91–92 °C; ¹H NMR (500 MHz, CDCl₃) δ 7.54 (d, *J* = 8.3 Hz, 2H), 7.34 (s, 4H), 7.25 (d, *J* = 8.3 Hz, 2H), 6.91 (s, 1H), 2.41 (s, 3H); ¹³C NMR (125 MHz, CDCl₃) δ 146.3, 144.9,

137.5, 137.0, 132.7, 131.4, 130.3, 129.8, 128.3, 127.8, 21.6; HRMS (APCI) calcd for C₁₅H₁₃BrClO₂S (M + H)⁺ 370.9508, found 370.9503.

(*E*)-1-(1-Chloro-2-tosylvinyl)-2-methylbenzene (**3ka**): white solid (105.5 mg, 69%); mp 80–81 °C; ¹H NMR (500 MHz, CDCl₃) δ 7.38 (d, *J* = 8.3 Hz, 2H), 7.30 (m, 1H), 7.17 (dd, *J* = 7.6, 5.3 Hz, 3H), 7.13–7.08 (m, 2H), 7.00 (s, 1H), 2.40 (s, 3H), 2.08 (s, 3H); ¹³C NMR (125 MHz, CDCl₃) δ 148.4, 144.6, 137.4, 135.9, 133.9, 132.6, 130.3, 130.2, 129.6, 128.6, 127.9, 125.5, 21.6, 19.1; HRMS (APCI) calcd for C₁₆H₁₆ClO₂S (M + H)⁺ 307.0560, found 307.0557.

(*E*)-1-Chloro-2-(1-chloro-2-tosylvinyl)benzene (**3la**): white solid (114.8 mg, 70%); mp 112–114 °C; ¹H NMR (500 MHz, CDCl₃) δ 7.52 (d, *J* = 8.3 Hz, 2H), 7.37–7.31 (m, 4H), 7.23 (d, *J* = 8.0 Hz, 2H), 6.97 (s, 1H), 2.41 (s, 3H); ¹³C NMR (126 MHz, CDCl₃) δ 144.9, 144.7, 137.0, 133.5, 133.0, 132.2, 131.4, 130.6, 129.7, 129.6, 128.0, 126.6, 21.6; HRMS (APCI) calcd for C₁₅H₁₃Cl₂O₂S (M + H)⁺ 327.0013, found 327.0011.

(*E*)-1-(1-Chloro-2-tosylvinyl)-3,5-bis(trifluoromethyl)benzene (**3ma**): white solid (130.9 mg, 61%); mp 169–170 °C; ¹H NMR (500 MHz, CDCl₃) δ 7.93 (s, 1H), 7.78 (s, 2H), 7.50 (d, *J* = 8.2 Hz, 2H), 7.25 (d, *J* = 8.1 Hz, 2H), 7.09 (s, 1H), 2.41 (s, 3H); ¹³C NMR (125 MHz, CDCl₃) δ 145.6, 143.4, 136.9, 136.4, 133.8, 131.7 (q, *J* = 33.9 Hz), 130.0, 129.0 (d, *J* = 2.8 Hz), 127.7, 124.1 (m), 122.8 (q, *J* = 271.4 Hz), 21.5; HRMS (APCI) calcd for C₁₇H₁₂ClF₆O₂S (M + H)⁺ 429.0151, found 429.0149.

(*E*)-2-(1-Chloro-2-tosylvinyl)thiophene (**3na**): brown solid (72.6 mg, 49%); mp 54–57 °C; ¹H NMR (500 MHz, CDCl₃) δ 7.79 (dd, *J* = 3.8, 1.1 Hz, 1H), 7.65 (d, *J* = 8.3 Hz, 2H), 7.54 (dd, *J* = 5.1, 1.1 Hz, 1H), 7.25 (d, *J* = 7.8 Hz, 2H), 7.05 (dd, *J* = 5.0, 3.8 Hz, 1H), 6.82 (s, 1H), 2.40 (s, 3H); ¹³C NMR (125 MHz, CDCl₃) δ 144.8, 139.9, 137.6, 135.3, 133.8, 131.5, 129.7, 129.3, 127.6, 127.4, 21.6; HRMS (APCI) calcd for C₁₃H₁₂ClO₂S₂ (M + H)⁺ 298.9967, found 298.9964.

(*E*)-1-((2-Chlorohept-1-en-1-yl)sulfonyl)-4-methylbenzene (**3oa**): pale oil (51.3 mg, 36%); ¹H NMR (500 MHz, CDCl₃) δ 7.78 (d, *J* = 8.3 Hz, 2H), 7.36 (d, *J* = 8.0 Hz, 2H), 6.52 (s, 1H), 2.95–2.91 (m, 2H), 2.45 (s, 3H), 1.62–1.56 (m, 2H), 1.32 (m, 4H), 0.89 (t, *J* = 6.9 Hz, 3H); ¹³C NMR (125 MHz, CDCl₃) δ 154.4, 144.8, 138.5, 130.0, 128.9, 127.4, 34.8, 30.9, 27.2, 22.3, 21.6, 13.8; HRMS (APCI) calcd for C₁₄H₂₀ClO₂S (M + H)⁺ 287.0873, found 287.0868.

(*E*)-1-((2-Bromo-2-phenylvinyl)sulfonyl)-4-methylbenzene (**4aa**):¹⁷ white solid (89.5 mg, 53%); mp 94–96 °C; ¹H NMR (500 MHz, CDCl₃) δ 7.49 (d, *J* = 8.3 Hz, 2H), 7.40–7.37 (m, 1H), 7.33 (dd, *J* = 4.9, 1.5 Hz, 4H), 7.20 (d, *J* = 8.0 Hz, 2H), 7.14 (s, 1H), 2.40 (s, 3H); ¹³C NMR (125 MHz, CDCl₃) δ 144.6, 138.3, 137.5, 136.1, 134.3, 130.4, 129.7, 128.6, 128.0, 127.9, 21.6.

(*E*)-1-(1-Bromo-2-(phenylsulfonyl)vinyl)benzene (**4ab**):¹⁷ white solid (64.5 mg, 40%); mp 77–78 °C; ¹H NMR (500 MHz, CDCl₃) δ 7.59 (dd, *J* = 8.3, 1.1 Hz, 2H), 7.54 (dd, *J* = 11.7, 4.2 Hz, 1H), 7.41–7.36 (m, 3H), 7.33–7.29 (m, 4H), 7.17 (s, 1H); ¹³C NMR (125 MHz, CDCl₃) δ 140.4, 138.8, 136.0, 134.2, 133.6, 130.5, 129.0, 128.6, 128.1, 127.8.

(*E*)-1-((2-Bromo-2-phenylvinyl)sulfonyl)-4-methoxybenzene (**4ac**):¹⁷ white solid (106.5 mg, 60%); mp 96–98 °C; ¹H NMR (500 MHz, CDCl₃) δ 7.51 (d, *J* = 8.9 Hz, 2H), 7.39–7.31 (m, 5H), 7.15 (s, 1H), 6.85 (d, *J* = 8.9 Hz, 2H), 3.84 (s, 3H); ¹³C NMR (125 MHz, CDCl₃) δ 163.7, 137.8, 136.2, 134.7, 131.9, 130.3, 130.0, 128.6, 128.0, 114.3, 55.7; HRMS (APCI) calcd for C₁₅H₁₄BrO₃S (M + H)⁺ 352.9847, found 352.9844.

(*E*)-1-((2-Bromo-2-phenylvinyl)sulfonyl)-4-chlorobenzene (**4ad**): white solid (86.2 mg, 48%); mp 124–125 °C; ¹H NMR (500 MHz, CDCl₃) δ 7.50–7.47 (m, 2H), 7.42–7.48 (m, 1H), 7.36–7.31 (m, 4H), 7.28 (dd, *J* = 8.3, 1.3 Hz, 2H), 7.16 (s, 1H); ¹³C NMR (125 MHz, CDCl₃) δ 140.3, 139.4, 138.8, 135.9, 134.1, 130.6, 129.3, 129.3, 128.6, 128.1; HRMS (APCI) calcd for C₁₄H₁₁BrClO₂S (M + H)⁺ 356.9352, found 356.9348.

(*E*)-1-Bromo-4-((2-bromo-2-phenylvinyl)sulfonyl)benzene (**4ae**): white solid (74.4 mg, 37%); mp 121–123 °C; ¹H NMR (500 MHz, CDCl₃) δ 7.51 (d, *J* = 8.7 Hz, 2H), 7.42–7.38 (m, 3H), 7.35–7.32 (m, 2H), 7.29–7.26 (m, 2H), 7.16 (s, 1H); ¹³C NMR (125 MHz, CDCl₃) δ 139.5, 139.3, 135.9, 134.0, 132.3, 130.6, 129.3, 128.9, 128.6, 128.1;

HRMS (APCI) calcd for $C_{14}H_{11}Br_2O_2S$ ($M + H$)⁺ 400.8847, found 400.8843.

(*E*)-1-((2-Bromo-2-(*p*-tolyl)vinyl)sulfonyl)-4-methylbenzene (**4ba**):¹² white solid (89.2 mg, 51%); mp 125–126 °C; ¹H NMR (500 MHz, CDCl₃) δ 7.52 (d, *J* = 8.3 Hz, 2H), 7.25 (d, *J* = 8.2 Hz, 2H), 7.22 (d, *J* = 8.0 Hz, 2H), 7.15 (d, *J* = 7.9 Hz, 2H), 7.08 (s, 1H), 2.40 (s, 3H), 2.38 (s, 3H); ¹³C NMR (125 MHz, CDCl₃) δ 144.6, 140.9, 138.7, 137.6, 133.7, 133.3, 129.7, 128.7, 128.6, 127.8, 21.6, 21.5.

(*E*)-1-((2-Bromo-2-(4-pentylphenyl)vinyl)sulfonyl)-4-methylbenzene (**4ca**): pale oil (101.6 mg, 50%); ¹H NMR (500 MHz, CDCl₃) δ 7.47 (d, *J* = 8.3 Hz, 2H), 7.24 (d, *J* = 8.2 Hz, 2H), 7.16 (d, *J* = 8.0 Hz, 2H), 7.12 (t, *J* = 4.1 Hz, 3H), 2.63–2.59 (m, 2H), 2.37 (s, 3H), 1.66–1.59 (m, 2H), 1.39–1.31 (m, 4H), 0.91 (t, *J* = 7.0 Hz, 3H); ¹³C NMR (125 MHz, CDCl₃) δ 145.9, 144.5, 138.8, 137.5, 136.5, 134.0, 129.6, 128.8, 128.0, 127.8, 35.8, 31.5, 30.9, 22.5, 21.6, 14.0; HRMS (APCI) calcd for $C_{20}H_{24}BrO_2S$ ($M + H$)⁺ 407.0680, found 407.0684.

(*E*)-1-((2-Bromo-2-(4-methoxyphenyl)vinyl)sulfonyl)-4-methylbenzene (**4da**):¹² white solid (99.5 mg, 54%); mp 101–103 °C; ¹H NMR (500 MHz, CDCl₃) δ 7.53 (d, *J* = 8.3 Hz, 2H), 7.34 (d, *J* = 8.8 Hz, 2H), 7.21 (d, *J* = 8.0 Hz, 2H), 7.06 (s, 1H), 6.84 (d, *J* = 8.8 Hz, 2H), 3.83 (s, 3H), 2.39 (s, 3H); ¹³C NMR (125 MHz, CDCl₃) δ 161.4, 144.6, 138.7, 137.7, 133.1, 130.8, 129.7, 128.2, 127.8, 113.3, 55.4, 21.6.

(*E*)-1-((2-Bromo-2-(4-fluorophenyl)vinyl)sulfonyl)-4-methylbenzene (**4ea**):¹² white solid (64.2 mg, 36%); mp 89–91 °C; ¹H NMR (500 MHz, CDCl₃) δ 7.52 (d, *J* = 8.3 Hz, 2H), 7.37–7.34 (m, 2H), 7.24 (d, *J* = 8.1 Hz, 2H), 7.13 (s, 1H), 7.03 (t, *J* = 8.6 Hz, 2H), 2.41 (s, 3H); ¹³C NMR (125 MHz, CDCl₃) δ 163.7 (d, *J* = 250.6 Hz), 144.9, 137.4, 136.9, 134.6, 132.1 (d, *J* = 3.4 Hz), 131.0 (d, *J* = 8.7 Hz), 129.8, 127.8, 115.2 (d, *J* = 22.0 Hz), 21.6.

(*E*)-1-((2-Bromo-2-(4-chlorophenyl)vinyl)sulfonyl)-4-methylbenzene (**4fa**): white solid (140.8 mg, 76%); mp 123–124 °C; ¹H NMR (500 MHz, CDCl₃) δ 7.52 (d, *J* = 8.3 Hz, 2H), 7.32 (d, *J* = 8.7 Hz, 2H), 7.28 (d, *J* = 8.7 Hz, 2H), 7.24 (d, *J* = 8.1 Hz, 2H), 7.13 (s, 1H), 2.41 (s, 3H); ¹³C NMR (125 MHz, CDCl₃) δ 145.0, 137.3, 136.7, 136.5, 134.8, 134.5, 130.1, 129.8, 128.3, 127.8, 21.6; HRMS (APCI) calcd for $C_{15}H_{13}BrClO_2S$ ($M + H$)⁺ 370.9508, found 370.9505.

(*E*)-1-Bromo-4-(1-bromo-2-tosylvinyl)benzene (**4ga**): white solid (141.5 mg, 68%); mp 137–139 °C; ¹H NMR (500 MHz, CDCl₃) δ 7.52 (d, *J* = 8.3 Hz, 2H), 7.48 (d, *J* = 8.5 Hz, 2H), 7.25 (d, *J* = 8.1 Hz, 2H), 7.21 (d, *J* = 8.5 Hz, 2H), 7.13 (s, 1H), 2.42 (s, 3H); ¹³C NMR (125 MHz, CDCl₃) δ 145.0, 137.3, 136.5, 135.0, 134.8, 131.3, 130.2, 129.8, 127.8, 125.0, 21.7; HRMS (APCI) calcd for $C_{15}H_{13}Br_2O_2S$ ($M + H$)⁺ 414.9003, found 414.9001.

(*E*)-1-Bromo-3-(1-bromo-2-tosylvinyl)benzene (**4ha**): white solid (97.5 mg, 47%); mp 111–112 °C; ¹H NMR (500 MHz, CDCl₃) δ 7.51–7.47 (m, 3H), 7.31–7.29 (m, 1H), 7.25–7.21 (m, 4H), 7.18 (s, 1H), 2.42 (s, 3H); ¹³C NMR (125 MHz, CDCl₃) δ 145.0, 137.8, 137.1, 135.7, 135.6, 133.2, 130.9, 129.8, 129.6, 127.9, 127.3, 121.9, 21.7; HRMS (APCI) calcd for $C_{15}H_{13}Br_2O_2S$ ($M + H$)⁺ 414.9003, found 414.9006.

(*E*)-1-(1-Bromo-2-tosylvinyl)-2-chlorobenzene (**4ia**): white solid (91.4 mg, 49%); mp 97–98 °C; ¹H NMR (500 MHz, CDCl₃) δ 7.53 (d, *J* = 8.3 Hz, 2H), 7.35–7.31 (m, 4H), 7.24 (d, *J* = 8.0 Hz, 2H), 7.16 (s, 1H), 2.42 (s, 3H); ¹³C NMR (125 MHz, CDCl₃) δ 145.0, 136.8, 135.9, 135.0, 134.3, 131.9, 131.2, 130.1, 129.8, 129.7, 128.0, 126.6, 21.7; HRMS (APCI) calcd for $C_{15}H_{13}BrClO_2S$ ($M + H$)⁺ 370.9508, found 370.9507.

(*E*)-1-(1-Bromo-2-tosylvinyl)-3,5-bis(trifluoromethyl)benzene (**4ja**): white solid (123.2 mg, 54%); mp 147–149 °C; ¹H NMR (500 MHz, CDCl₃) δ 7.88 (s, 1H), 7.71 (s, 2H), 7.48 (d, *J* = 8.3 Hz, 2H), 7.30 (s, 1H), 7.24 (d, *J* = 8.1 Hz, 2H), 2.41 (s, 3H); ¹³C NMR (125 MHz, CDCl₃) δ 145.6, 138.1, 137.1, 136.7, 133.0, 131.7 (q, *J* = 33.8 Hz), 130.0, 128.7 (d, *J* = 3.2 Hz), 127.7, 123.8 (m), 122.7 (q, *J* = 271.3 Hz), 21.5; HRMS (APCI) calcd for $C_{17}H_{12}BrF_6O_2S$ ($M + H$)⁺ 472.9646, found 472.9641.

(*E*)-2-(1-Bromo-2-tosylvinyl)thiophene (**4ka**): brown solid (71.9 mg, 42%); mp 84–86 °C; ¹H NMR (500 MHz, CDCl₃) δ 7.67 (dd, *J*

= 3.8, 1.2 Hz, 1H), 7.62 (d, *J* = 8.3 Hz, 2H), 7.53 (dd, *J* = 5.1, 1.2 Hz, 1H), 7.25 (d, *J* = 8.0 Hz, 2H), 7.07 (s, 1H), 7.04 (dd, *J* = 5.1, 3.8 Hz, 1H), 2.40 (s, 3H); ¹³C NMR (125 MHz, CDCl₃) δ 144.8, 137.3, 137.1, 133.3, 133.3, 131.3, 129.7, 129.4, 127.7, 127.3, 21.6; HRMS (APCI) calcd for $C_{13}H_{12}BrO_2S_2$ ($M + H$)⁺ 342.9462, found 342.9465.

(*E*)-1-((2-Bromohept-1-en-1-yl)sulfonyl)-4-methylbenzene (**4la**):¹² pale oil (59.6 mg, 36%); ¹H NMR (500 MHz, CDCl₃) δ 7.71 (d, *J* = 8.3 Hz, 2H), 7.29 (d, *J* = 8.0 Hz, 2H), 6.68 (s, 1H), 2.98–2.95 (m, 2H), 2.38 (s, 3H), 1.54–1.50 (m, 2H), 1.25 (m, 4H), 0.83 (t, *J* = 6.9 Hz, 3H); ¹³C NMR (125 MHz, CDCl₃) δ 146.7, 144.9, 138.3, 132.1, 130.1, 127.5, 36.8, 30.8, 28.1, 22.4, 21.7, 13.9.

■ ASSOCIATED CONTENT

📄 Supporting Information

Copies of ¹H and ¹³C NMR spectra for all products. This material is available free of charge via the Internet at <http://pubs.acs.org>.

■ AUTHOR INFORMATION

✉ Corresponding Author

*E-mail: xqli@zjut.edu.cn, future@zjut.edu.cn.

Notes

The authors declare no competing financial interest.

■ ACKNOWLEDGMENTS

We thank the National Natural Science Foundation of China (21102130) and the Key Innovation Team of Science & Technology in Zhejiang Province (2010RS0018 and 2011RS0017) for financial support.

■ REFERENCES

- (1) For recent selected examples of difunctionalization of terminal alkyne, see: (a) Goossen, L. J.; Rodríguez, N.; Goossen, K. *Angew. Chem., Int. Ed.* **2009**, *48*, 9592. (b) Mizuno, A.; Kusama, H.; Iwasawa, N. *Angew. Chem., Int. Ed.* **2009**, *48*, 8318. (c) Sha, F.; Huang, X. *Angew. Chem., Int. Ed.* **2009**, *48*, 3458. (d) Ye, L.; Cui, L.; Zhang, G.; Zhang, L. *J. Am. Chem. Soc.* **2010**, *132*, 3258. (e) Dutta, B.; Gilboa, N.; Marek, I. *J. Am. Chem. Soc.* **2010**, *132*, 5588. (f) Zhang, C.; Jiao, N. *J. Am. Chem. Soc.* **2010**, *132*, 28. (g) Kuang, J.; Ma, S. *J. Am. Chem. Soc.* **2010**, *132*, 1786. (h) Li, Y.; Liu, X.; Ma, D.; Liu, B.; Jiang, H. *Adv. Synth. Catal.* **2012**, *354*, 2683. (i) Chen, Z.; Li, J.; Jiang, H.; Zhu, S.; Li, Y.; Qi, C. *Org. Lett.* **2010**, *12*, 3262.
- (2) (a) Amiel, Y. *Tetrahedron Lett.* **1971**, *8*, 661. (b) Amiel, Y. *J. Org. Chem.* **1971**, *36*, 3691. (c) Amiel, Y. *J. Org. Chem.* **1971**, *36*, 3697. (d) Liu, X.; Duan, X.; Pan, Z.; Han, Y.; Liang, Y. *Synlett* **2005**, *11*, 1752.
- (3) (a) Truce, W. E.; Wolf, G. C. *J. Org. Chem.* **1971**, *36*, 1727. (b) Amiel, Y. *J. Org. Chem.* **1974**, *39*, 3867.
- (4) For recent selected examples, see: (a) Corbet, J. P.; Mignani, G. *Chem. Rev.* **2006**, *106*, 2651. (b) Cahiez, G.; Moyeux, A. *Chem. Rev.* **2010**, *110*, 1435. (c) Amatore, C.; Jutand, A. *Acc. Chem. Res.* **2000**, *33*, 314. (d) Bettinger, H. F.; Filthaus, M. *J. Org. Chem.* **2007**, *72*, 9750. (e) Uchiyama, M.; Furuyama, T.; Kobayashi, M.; Matsumoto, Y.; Tanaka, K. *J. Am. Chem. Soc.* **2006**, *128*, 8404. (f) Boukouvalas, J.; Loach, R. P. *J. Org. Chem.* **2008**, *73*, 8109.
- (5) For recent selected examples, see: (a) Kumar, R.; Kumar, T.; Mobin, S. M.; Nambhothiri, I. N. *J. Org. Chem.* **2013**, *78*, 5073. (b) Opekar, S.; Pohl, R.; Eigner, V.; Beier, P. *J. Org. Chem.* **2013**, *78*, 4573. (c) Urones, B.; Arrayas, R. G.; Carretero, J. C. *Org. Lett.* **2013**, *15*, 1120. (d) Suresh, R. C.; Wiczysty, M. D.; Khan, I.; Lam, H. W. *Org. Lett.* **2013**, *15*, 570. (e) Zhao, P.; Beaudry, C. M. *Org. Lett.* **2013**, *15*, 402. (f) Huang, Z.; Kaur, J.; Bhardwaj, A.; Alsaleh, N. *J. Med. Chem.* **2012**, *55*, 10262.
- (6) Zeng, X.; Iliés, L.; Nakamura, E. *Org. Lett.* **2012**, *14*, 954.
- (7) (a) Li, X.; Xu, X.; Zhou, C. *Chem. Commun.* **2012**, *48*, 12240. (b) Li, X.; Xu, X.; Hu, P.; Xiao, X.; Zhou, C. *J. Org. Chem.* **2013**, *78*,

7343. (c) Li, X.; Xu, X.; Tang, Y. *Org. Biomol. Chem.* **2013**, *11*, 1739.
(d) Li, X.; Xu, X.; Shi, X. *Tetrahedron Lett.* **2013**, *54*, 3071.
(8) Taniguchi, T.; Fujii, T.; Ishibashi, H. *J. Org. Chem.* **2010**, *75*, 8126.
(9) The compounds **3aa**, **3ac**, **3ad**, **3da**, and **3fa** are synthesized in 66, 55, 67, 52, and 63% yields, respectively, in ref 6.
(10) Liu, W.; Li, Y.; Liu, K.; Li, Z. *J. Am. Chem. Soc.* **2011**, *133*, 10756.
(11) Taniguchi, N. *Synlett* **2011**, 1308.
(12) Gilmore, K.; Gold, B.; Alabugin, L. V. *Aust. J. Chem.* **2013**, *66*, 336.